vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and MSCI Inc. (MSCI). Click either name above to swap in a different company.

Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $822.5M, roughly 1.2× MSCI Inc.). MSCI Inc. runs the higher net margin — 34.6% vs 0.7%, a 33.9% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 10.6%). MSCI Inc. produced more free cash flow last quarter ($488.7M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 10.0%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

MSCI Inc. is an American finance company headquartered in New York City. MSCI is a global provider of equity, fixed income, real estate indices, multi-asset portfolio analysis tools, ESG and climate finance products. It operates the MSCI World, MSCI Emerging Markets, and MSCI All Country World (ACWI) indices, among others.

ASTH vs MSCI — Head-to-Head

Bigger by revenue
ASTH
ASTH
1.2× larger
ASTH
$950.5M
$822.5M
MSCI
Growing faster (revenue YoY)
ASTH
ASTH
+32.3% gap
ASTH
42.9%
10.6%
MSCI
Higher net margin
MSCI
MSCI
33.9% more per $
MSCI
34.6%
0.7%
ASTH
More free cash flow
MSCI
MSCI
$494.6M more FCF
MSCI
$488.7M
$-6.0M
ASTH
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
10.0%
MSCI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASTH
ASTH
MSCI
MSCI
Revenue
$950.5M
$822.5M
Net Profit
$6.6M
$284.7M
Gross Margin
Operating Margin
1.9%
56.4%
Net Margin
0.7%
34.6%
Revenue YoY
42.9%
10.6%
Net Profit YoY
184.4%
-6.8%
EPS (diluted)
$0.12
$3.81

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
MSCI
MSCI
Q4 25
$950.5M
$822.5M
Q3 25
$956.0M
$793.4M
Q2 25
$654.8M
$772.7M
Q1 25
$620.4M
$745.8M
Q4 24
$665.2M
$743.5M
Q3 24
$478.7M
$724.7M
Q2 24
$486.3M
$707.9M
Q1 24
$404.4M
$680.0M
Net Profit
ASTH
ASTH
MSCI
MSCI
Q4 25
$6.6M
$284.7M
Q3 25
$373.0K
$325.4M
Q2 25
$9.4M
$303.6M
Q1 25
$6.7M
$288.6M
Q4 24
$-7.8M
$305.5M
Q3 24
$16.1M
$280.9M
Q2 24
$19.2M
$266.8M
Q1 24
$14.8M
$256.0M
Operating Margin
ASTH
ASTH
MSCI
MSCI
Q4 25
1.9%
56.4%
Q3 25
2.0%
56.4%
Q2 25
3.1%
55.0%
Q1 25
3.3%
50.6%
Q4 24
0.1%
54.5%
Q3 24
5.9%
55.4%
Q2 24
6.2%
54.0%
Q1 24
7.5%
49.9%
Net Margin
ASTH
ASTH
MSCI
MSCI
Q4 25
0.7%
34.6%
Q3 25
0.0%
41.0%
Q2 25
1.4%
39.3%
Q1 25
1.1%
38.7%
Q4 24
-1.2%
41.1%
Q3 24
3.4%
38.8%
Q2 24
3.9%
37.7%
Q1 24
3.7%
37.6%
EPS (diluted)
ASTH
ASTH
MSCI
MSCI
Q4 25
$0.12
$3.81
Q3 25
$0.01
$4.25
Q2 25
$0.19
$3.92
Q1 25
$0.14
$3.71
Q4 24
$-0.14
$3.89
Q3 24
$0.33
$3.57
Q2 24
$0.40
$3.37
Q1 24
$0.31
$3.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
MSCI
MSCI
Cash + ST InvestmentsLiquidity on hand
$429.5M
$515.3M
Total DebtLower is stronger
$6.2B
Stockholders' EquityBook value
$779.3M
$-2.7B
Total Assets
$2.2B
$5.7B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
MSCI
MSCI
Q4 25
$429.5M
$515.3M
Q3 25
$463.4M
$400.1M
Q2 25
$342.1M
$347.3M
Q1 25
$260.9M
$360.7M
Q4 24
$290.8M
$409.4M
Q3 24
$350.3M
$501.0M
Q2 24
$327.7M
$451.4M
Q1 24
$337.3M
$519.3M
Total Debt
ASTH
ASTH
MSCI
MSCI
Q4 25
$6.2B
Q3 25
$5.5B
Q2 25
$4.5B
Q1 25
$4.5B
Q4 24
$4.5B
Q3 24
$4.5B
Q2 24
$4.5B
Q1 24
$4.5B
Stockholders' Equity
ASTH
ASTH
MSCI
MSCI
Q4 25
$779.3M
$-2.7B
Q3 25
$775.5M
$-1.9B
Q2 25
$765.5M
$-886.2M
Q1 25
$745.4M
$-958.6M
Q4 24
$712.7M
$-940.0M
Q3 24
$704.6M
$-751.0M
Q2 24
$678.9M
$-734.5M
Q1 24
$653.5M
$-650.5M
Total Assets
ASTH
ASTH
MSCI
MSCI
Q4 25
$2.2B
$5.7B
Q3 25
$2.2B
$5.4B
Q2 25
$1.4B
$5.4B
Q1 25
$1.3B
$5.3B
Q4 24
$1.4B
$5.4B
Q3 24
$1.3B
$5.4B
Q2 24
$1.3B
$5.5B
Q1 24
$1.2B
$5.5B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
MSCI
MSCI
Operating Cash FlowLast quarter
$-2.9M
$501.1M
Free Cash FlowOCF − Capex
$-6.0M
$488.7M
FCF MarginFCF / Revenue
-0.6%
59.4%
Capex IntensityCapex / Revenue
0.3%
1.5%
Cash ConversionOCF / Net Profit
-0.44×
1.76×
TTM Free Cash FlowTrailing 4 quarters
$104.5M
$1.5B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
MSCI
MSCI
Q4 25
$-2.9M
$501.1M
Q3 25
$10.0M
$449.4M
Q2 25
$90.9M
$336.1M
Q1 25
$16.6M
$301.7M
Q4 24
$-10.9M
$430.6M
Q3 24
$34.0M
$421.6M
Q2 24
$23.2M
$349.2M
Q1 24
$6.0M
$300.1M
Free Cash Flow
ASTH
ASTH
MSCI
MSCI
Q4 25
$-6.0M
$488.7M
Q3 25
$7.4M
$445.5M
Q2 25
$89.5M
$324.7M
Q1 25
$13.6M
$290.2M
Q4 24
$-13.5M
$416.4M
Q3 24
$31.7M
$415.0M
Q2 24
$20.4M
$340.6M
Q1 24
$5.6M
$295.9M
FCF Margin
ASTH
ASTH
MSCI
MSCI
Q4 25
-0.6%
59.4%
Q3 25
0.8%
56.2%
Q2 25
13.7%
42.0%
Q1 25
2.2%
38.9%
Q4 24
-2.0%
56.0%
Q3 24
6.6%
57.3%
Q2 24
4.2%
48.1%
Q1 24
1.4%
43.5%
Capex Intensity
ASTH
ASTH
MSCI
MSCI
Q4 25
0.3%
1.5%
Q3 25
0.3%
0.5%
Q2 25
0.2%
1.5%
Q1 25
0.5%
1.5%
Q4 24
0.4%
1.9%
Q3 24
0.5%
0.9%
Q2 24
0.6%
1.2%
Q1 24
0.1%
0.6%
Cash Conversion
ASTH
ASTH
MSCI
MSCI
Q4 25
-0.44×
1.76×
Q3 25
26.69×
1.38×
Q2 25
9.65×
1.11×
Q1 25
2.48×
1.05×
Q4 24
1.41×
Q3 24
2.11×
1.50×
Q2 24
1.21×
1.31×
Q1 24
0.40×
1.17×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

MSCI
MSCI

Recurring Subscriptions$246.4M30%
Asset Based Fees$211.7M26%
Analytics Segment$182.3M22%
Sustainability And Climate Segment$90.3M11%
Other$70.9M9%
Non Recurring$21.1M3%

Related Comparisons